Figure 2. Risk of the Primary Composite End Point, and Treatment Effect of Vericiguat Compared With Placebo, Analyzed by Finer Cuts of Time From Index Heart Failure (HF) Event (A) as Well as Using Time From Index Hospitalization as a Continuous Variable (B).

A, Incidence rates (and their 95% confidence intervals) of the primary composite end point are shown according to finer cuts of time from index event. Data on days to index event were missing in 16 patients. B, The treatment effect of vericiguat (hazard ratio [HR] with 95% confidence interval) is shown as a function of time as a continuous variable from index event to randomization among hospitalized patients. Data are presented for 4219 patients randomized within 200 days.